---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292016"
form_type: "8-K"
ticker: null
cik: "0001907685"
company_name: "Comera Life Sciences Holdings, Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:39:06.594891+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq warns Comera Life Sciences of MVLS deficiency; 180-day cure period ends May 17, 2023

## Summary
- MVLS has been below $35M minimum for 30 consecutive business days, violating Nasdaq rule 5550(b)(2).
- Compliance period runs until May 17, 2023; must close at $35M+ for ten consecutive days.
- Alternative: meet minimum stockholders' equity of $2.5M to regain compliance.
- No immediate impact on listing; stock continues trading on Nasdaq Capital Market under CMRA.
- Company will monitor and evaluate options, but delisting risk remains if deficiency not cured.

## SEC filing metadata
- accession: 0001193125-22-292016
- form_type: 8-K
- cik: 0001907685
- company_name: Comera Life Sciences Holdings, Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907685/000119312522292016/0001193125-22-292016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907685/000119312522292016/d410213d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292016
- JSON: https://secwatch.observer/filing/0001193125-22-292016.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292016.txt

## Key facts
- Listing & Compliance Notices
  Comera Life Sciences Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2), 5810(c)(3)(C)
  source text: November 18, 2022, Comera Life Sciences Holdings, Inc. (the “Company”) received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq listing rule 5550(b)(2). The notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Cap
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907685/000119312522292016/0001193125-22-292016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.